Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients

Background: This meta-analysis aimed to test the hypothesis that the HER2-positive metastatic breast cancer (mBC) patients treated with anti-HER2 antibodies in trial intervention arms have a greater prolongation of overall survival (OS) than of progression-free survival (PFS) and this extra-prolonga...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	I-Chun Chen, Fu-Chang Hu, Ching-Hung Lin, Shu-Min Huang, Dwan-Ying Chang, Ann-Lii Cheng, Yen-Shen Lu
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Elsevier 2021-10-01
Reeks:	Breast
Onderwerpen:	HER2 Progression-free survival Overall survival Metastatic breast cancer
Online toegang:	http://www.sciencedirect.com/science/article/pii/S0960977621004148
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!